Diploma Shares Surge on Upgraded FY26 Guidance

Shares in Diploma PLC (LON: DPLM) are surging following the release of a trading update that reflects strong trading performance and an upgraded financial outlook for fiscal year 2026.

The value-add solutions group’s announcement has instilled confidence in the market, driving positive price action.

The company has raised its organic revenue growth forecast for FY26 to 9%, up from the previous estimate of 6%. This growth is expected to be weighted towards the first half of the year.

Net acquisition growth remains unchanged at 3%, with potential for further increases should additional acquisitions materialize.

Notably, Diploma PLC has significantly increased its operating margin guidance to approximately 25%, a substantial rise from the previous target of around 22.5%. This upgrade translates to an approximate 13% increase to consensus operating profit estimates.

The company anticipates another year of sustainable quality compounding, with earnings growth exceeding 20% alongside strong returns on capital.

Diploma PLC is experiencing robust growth across its diversified portfolio. The Controls segment is a key driver, with Peerless benefiting from favorable and sustainable aerospace demand and supply dynamics.

Other Controls businesses, including IS Group and Clarendon, are also performing well in structurally growing markets such as energy, defense, and aerospace. Windy City Wire is demonstrating strong growth, supported by excellent execution in markets including data centers and digital antenna systems.

The Seals segment is showing mixed performance. North American Seals is progressing well, with strong core business growth in infrastructure and promising developments in nuclear power generation. However, International Seals, particularly in the UK, continues to face challenges, which are somewhat holding back overall Seals H1 growth rates, consistent with FY25.

The Life Sciences segment is performing consistently in a challenging healthcare market, gaining market share across medtech and IVD. Organic growth, excluding Peerless, remains strong and exceeds the company’s financial model projections.

Margins are expanding, driven by accretive contributions from Peerless and steady accretion across the rest of the Group.

The company’s acquisition momentum continues, with eight acquisitions completed in the preceding two quarters for approximately £130 million, expected to contribute around £20 million in annualized operating profit.